爱尔眼科(300015) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was RMB 5.756 billion, a decrease of 0.68% year-over-year[3] - Net profit attributable to shareholders was RMB 1.402 billion, down 4.56% year-over-year[3] - Total revenue for the period reached RMB 16.30 billion, a slight increase from RMB 16.05 billion in the previous year[19] - Net profit attributable to parent company shareholders was RMB 3.45 billion, up from RMB 3.18 billion in the same period last year[20] - Basic earnings per share increased to RMB 0.3746 from RMB 0.3453 year-over-year[21] - Total comprehensive income for the period was RMB 3.66 billion, compared to RMB 3.52 billion in the previous year[21] Cash Flow and Operating Activities - Operating cash flow for the first nine months was RMB 4.299 billion, a decrease of 22.88% year-over-year[3] - Operating cash flow from sales and services was RMB 16.06 billion, up from RMB 15.66 billion in the previous year[22] - Operating cash inflow totaled 16,292,338,112.42 RMB, a slight increase from 15,958,709,458.14 RMB in the previous period[23] - Operating cash outflow increased to 11,993,575,517.60 RMB from 10,384,336,600.64 RMB, primarily driven by higher payments for goods, services, and employee compensation[23] - Net cash flow from operating activities decreased to 4,298,762,594.82 RMB from 5,574,372,857.50 RMB[23] - Net cash flow from investing activities was -2,419,173,893.02 RMB, compared to -2,373,367,243.03 RMB in the previous period[23] - Net cash flow from financing activities was -3,114,958,510.84 RMB, a significant decrease from -2,414,019,859.71 RMB[24] - Cash and cash equivalents at the end of the period were 4,852,300,253.65 RMB, down from 6,793,419,319.65 RMB[24] - Payments for employee compensation increased to 4,974,774,418.08 RMB from 4,206,346,978.03 RMB[23] - Payments for taxes and fees rose to 838,522,341.58 RMB from 761,631,256.67 RMB[23] - Cash received from investments decreased to 974,418,665.10 RMB from 1,100,936,682.02 RMB[23] - Cash paid for acquisitions of subsidiaries and other business units increased to 1,856,519,537.87 RMB from 1,102,763,856.82 RMB[23] Assets and Liabilities - Total assets increased by 9.25% to RMB 32.979 billion compared to the end of the previous year[3] - Fixed assets increased by 31.85% to RMB 5.095 billion due to new hospital acquisitions and subsidiary openings[6] - Goodwill increased by 33.43% to RMB 8.717 billion due to cash payments for non-controlling equity acquisitions[6] - Total assets increased from 30,186,619,945.52 yuan to 32,979,353,178.25 yuan[17] - Fixed assets increased from 3,864,318,150.30 yuan to 5,094,963,750.91 yuan[16] - Goodwill increased from 6,532,827,966.38 yuan to 8,716,742,506.98 yuan[17] - Short-term borrowings decreased from 850,366,666.67 yuan to 700,312,500.00 yuan[17] - Accounts payable increased from 1,809,292,666.97 yuan to 2,234,546,252.26 yuan[17] - Total current liabilities increased from 6,011,230,680.34 yuan to 6,681,450,808.73 yuan[17] - Total liabilities increased to RMB 11.44 billion from RMB 10.16 billion at the beginning of the period[18] - Total equity rose to RMB 21.54 billion, compared to RMB 20.02 billion at the start of the period[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 372,778[9] - Aier Medical Investment Group holds 34.33% of the shares, totaling 455,735,194 shares[9] - Chen Bang holds 15.48% of the shares, totaling 210,068,746 shares, with 1,082,843,918 shares under lock-up[9] - Li Li holds 3.46% of the shares, totaling 101,513,370 shares, with 242,261,245 shares under lock-up[9] - Hong Kong Securities Clearing Company holds 2.29% of the shares[9] - China Bank - Huabao CSI Medical ETF holds 1.68% of the shares[9] - Industrial and Commercial Bank of China - China Europe Medical Health Mixed Fund holds 1.56% of the shares, totaling 145,831,330 shares[10] - Industrial and Commercial Bank of China - E Fund ChiNext ETF holds 1.26% of the shares, totaling 117,632,766 shares[10] - Guo Hongwei holds 1.07% of the shares, totaling 100,000,000 shares[10] - Industrial and Commercial Bank of China - Huatai-PineBridge CSI 300 ETF holds 0.95% of the shares, totaling 88,476,005 shares[10] - Total restricted shares at the end of the period: 1,422,010,383 shares[14] Expenses and Investments - Financial expenses surged by 120.03% to RMB 140.818 million due to increased lease interest expenses and exchange rate fluctuations[7] - Investment income rose by 431.10% to RMB 148.922 million due to increased returns from financial products[7] - R&D expenses decreased to RMB 233.15 million from RMB 246.03 million year-over-year[20] - Sales expenses increased to RMB 1.64 billion, up from RMB 1.61 billion in the same period last year[20] - Cash paid for acquisitions of subsidiaries increased by 68.35% to RMB 1.857 billion[8] - Dividends and interest payments increased by 82.35% to RMB 1.649 billion[8] Monetary Funds - Monetary funds decreased from 6,099,082,253.65 yuan to 4,855,500,253.65 yuan[16]